Related Experiment Video
Updated: Dec 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Preconceived notions about biosimilars-a French experience
Jean-David Cohen1, Sonia Tropé2, Pascal Paubel3,4,5
1Rheumatology Department, Lapeyronie Hospital, Montpellier University Hospital Center, Montpellier, France. jd-cohen@chu-montpellier.fr.
Biosimilar monoclonal antibodies offer economic benefits but face misconceptions. This review clarifies facts versus myths for patients and healthcare professionals regarding these important therapies.
Area of Science:
- Pharmacology
- Biotechnology
- Health Economics
Background:
- The introduction of biosimilar monoclonal antibodies has led to widespread information and misconceptions among patients and healthcare professionals.
- A growing number of biosimilars are entering the market, intensifying the need for accurate information.
Discussion:
- This review aims to differentiate factual information from prevalent misconceptions surrounding biosimilar monoclonal antibodies.
- A multidisciplinary team including clinicians, patient advocates, biologists, pharmacists, and health economists contributed to this analysis.
Key Insights:
- Biosimilars represent a significant opportunity for cost savings in healthcare.
- Addressing misconceptions is crucial for patient and professional acceptance and optimal utilization of biosimilars.
Outlook:
- Further education and clear communication are essential to foster informed decision-making regarding biosimilar monoclonal antibodies.
- Continued research and real-world evidence will further support the understanding and adoption of biosimilars.
More Related Videos
07:52A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
Published on: April 9, 2019
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Bioequivalence: Overview
Equivalence: In Vitro and In Vivo Bioequivalence
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications